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Abstract
Background: Cystic Echinococosis (CE) is a zoonotic disease caused by larval stage Echinococcus granulosus. We determined
the effects of high dose of Oxfendazole (OXF), combination Oxfendazole/Praziquantel (PZQ), and combination Albendazole
(ABZ)/Praziquantel against CE in sheep.
Methodology/Principal Findings: A randomized placebo-controlled trial was carried out on 118 randomly selected ewes.
They were randomly assigned to one of the following groups: 1) placebo; 2) OXF 60 mg/Kg of body weight (BW) weekly for
four weeks; 3) ABZ 30 mg/Kg BW + PZQ 40 mg/Kg BW weekly for 6 weeks, and 4) OXF 30 mg/Kg BW+ PZQ 40 mg/Kg BW
biweekly for 3 administrations (6 weeks). Percent protoscolex (PSC) viability was evaluated using a 0.1% aqueous eosin vital
stain for each cyst. ‘‘Noninfective’’ sheep were those that had no viable PSCs; ‘‘low-medium infective’’ were those that had 1%
to60%PSCviability;and‘‘highinfective’’werethosewithmorethan60%PSCviability.Weevaluated92ofthe 118sheep.ABZ/
PZQ led the lowest PSC viability for lung cysts (12.7%), while OXF/PZQ did so for liver cysts (13.5%). The percentage of either
‘‘noninfective’’ or ‘‘low-medium infective’’ sheep was 90%, 93.8% and 88.9% for OXF, ABZ/PZQ and OXF/PZQ group as
compared to 50% ‘‘noninfective’’ or ‘‘low-medium infective’’ for placebo. After performing all necropsies, CE prevalence in the
flock of sheep was 95.7% (88/92) with a total number of 1094 cysts (12.4 cysts/animal). On average, the two-drug-combination
groups resulted pulmonary cysts that were 6 mm smaller and hepatic cysts that were 4.2 mm smaller than placebo (p,0.05).
Conclusions/Significance: We demonstrate that Oxfendazole at 60 mg, combination Oxfendazole/Praziquantel and
combination Albendazole/Praziquantel are successful schemas that can be added to control measures in animals and merits
further study for the treatment of animal CE. Further investigations on different schedules of monotherapy or combined
chemotherapy are needed, as well as studies to evaluate the safety and efficacy of Oxfendazole in humans.
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Introduction
Cystic Echinococosis (CE) is a zoonotic disease caused by larval
stage or metacestode of Echinococcus granulosus. It is recognized as a
major economic and public health problem in many areas
worldwide [1–3]. The intermediate hosts include sheep, goats,
cattle, horses, swine, and other wild ruminants; humans can be
considered as accidental hosts. The larval stage frequently inhabits
the liver and lungs both in humans and animals [4]. The hydatid
cyst then expands and can contain hundreds or thousands of PSCs
that can develop into the adult tapeworm upon ingestion by the
definitive host, typically dogs, wolves, and wild canids [5,6].
When surgery is not an option as first-line treatment for humans,
antiparasitic drugs areused in the treatment of CE[5,7,8].Through
animal trials, mebendazole and albendazole (ABZ) have been
shown effective against both E. granulosus and E. multilocularis larval
stages [9-15]. The current chemotherapy for human CE is 2-4
cycles of ABZ for 30 to 60 days with 15-days breaks between cycles
[5,14]. A review of ABZ uses found that the proportion of cured
cysts ranged from 11.8% to 35.2%, while between 22.4% to 50.0%
remained unchanged [14,15]. ABZ treatment is associated with
anomalies in hepatic function, leukopenia and alopecia among
other side effects [14–16]. Despite the questionable efficacy and
high cost, ABZ remains the best treatment option for inoperable
human cases and is the drug of choice for perioperative prophylaxis
[1] due to the lack of alternative drugs against hydatid cysts.
ABZ, along with levamisol and ivermectin, is also one of the
most used antiparasitic drug in sheep, goats, cattle, horses and
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trematodes [17]. Although ABZ is still regularly used in Australia,
Africa, Europe, North and South America, reports of nematode
resistance have emanated from those areas [18]. It has been shown
that ABZ is not detected in the plasma of treated sheep at any time
after administration, nevertheless, its active metabolites, albenda-
zole sulphoxide and albendazole sulphone are detectable for about
48 hr after administration. Albendazole sulphoxide is the most
important antihelmintic active metabolic product recovered from
the bloodstream after treatment of sheep with ABZ [19]. The
antiparasitic activity of the active metabolite depends largely not
only on its affinity for parasite b-tubulin, but also on its ability to
reach high and sustained concentrations at the site of parasite
location [20].
Oxfendazole (OXF), another benzimidazole like ABZ, has
broad-spectrum activity against larval stages of gastrointestinal
roundworms, tapeworms, and lungworms in many animal spe-
cies [21]. OXF has not yet been approved for human use making
an enormous disadvantage compared with ABZ. However, while
the main ABZ active metabolite (albendazole sulfoxide) can be
found in plasma for 60 hours post-treatment, OXF (active drug)
can be found in plasma up to 144 hours post-treament in a
comparative plasma availability study in sheep [22]. Animal
studies have demonstrated that administering OXF in doses of
30 mg/Kg for 11 consecutive weeks (sheep) [23,24] or biweekly
for 4 weeks (goats) [25] results in efficacies greater than 90%
against cystic echinococcosis. OXF has also been evaluated in
combination with Nitazoxanide in sheep, and it was shown that
most of the effect against hydatid cysts was attributable to the
OXF [23].
Although OXF has been evaluated in sheep and goats, there are
no clinical trials in sheep to determine the efficacy of higher
dosages of OXF in shorter periods of treatment. Also, there is not
information concerning the efficacy of combination with other
antiparasitic drugs rather than Nitazoxanide. We investigated in a
randomized placebo-controlled trial the effects of OXF alone as
well as the combinations of OXF/PZQ and ABZ/PZQ against
CE in naturally-infected sheep.
Methods
Study design
We performed a randomized placebo-controlled trial and
selected 118 ewes, which were then assigned to one of the three
treatment groups or a placebo group. Sheep were identified and
treated under different dosage schedules. The ewes were then
sacrificed 4 to 8 weeks after the last treatment for collection and
evaluation of lungs and livers. We counted the number of cysts in
each organ, and observed their morphological characteristics,
fertility status, and PSC viability to estimate the treatment efficacy.
The study was approved by the ethical review boards of the
Universidad Nacional Mayor de San Marcos, School of
Veterinary Medicine. We tested the hypothesis that OXF in
higher doses or combined with PZQ would reduce the PSC
viability and the cyst size in both lung and liver hydatid cysts.
Animals
Sheep were obtained from the Tupac Amaru, ranching
cooperative located in the Peruvian Central Highlands. This area
has a high prevalence of CE in sheep (87%), and humans (9.1%) as
previously reported [26]. Sheep were selected and assigned to
groups in two steps. First, a total of 118 Junin-breed ewes with
eight-tooth erupted (28 to 48 months of age) were randomly
selected by applying systematic random sampling procedure in a
corral from a flock of 700 sheep already determined for culling by
the cooperative. Animals that were clinically sick and unable to
move and feed by themselves were excluded before applying the
systematic randomization. Each selected sheep was identified using
numbered ear tags at the beginning of the study. Next, having a
list with those selected and numbered sheep, a simple random
procedure to allocate the animals into four groups was applied.
These animals were maintained in the same corral with the rest of
the flock under identical food and water availability. Animal
conditions were monitored prior to and throughout the experi-
mental period.
Treatment groups
Sheep were randomly assigned into four groups as follows: 1)
placebo; 2) OXF 60 mg/Kg of body weight (BW) weekly for four
weeks; 3) ABZ 30 mg/Kg BW + PZQ 40 mg/Kg BW weekly for 6
weeks, and 4) OXF 30 mg/Kg BW+ PZQ 40 mg/Kg BW
biweekly for 3 doses (6 weeks). The placebo group received a mix
of flour with water and was handled under similar conditions for 6
weeks to cause the same stress as the other groups. For the
combination groups, we gave the treatments separately; the drugs
were kept in their original bottles and they were not mixed
together.
All drugs were given using an oral drench via a Hauptner
automatic oral dose syringe (Nasco, Modesto, CA) and were
administered from a bottle suspension of oxfendazole (Synanthic
22.5% solution), or Albendazole (Vetalben, 15%) or Praziquantel
(Saniquantrel, 10%). The cost of each dose of OXF for an average
weight sheep (45 Kg) was US$0.36 at 30 mg/kg BW and US$0.72
at 60 mg/Kg BW. The combination of ABZ/PZQ as a single dose
costs US$0.64 for an average weight sheep, and the combination
of OXF/PZQ as a single dose costs US$0.88. Animals were
checked 3–5 minutes after administration to ensure that they had
swallowed the full dose of medication.
Sample size calculation
The sample size was estimated using the formula for testing
differences of two proportions, using a two-sided test with
significance level a=0.05 and power of 80%, with equal size for
Author Summary
Cystic Echinococcosis (CE) is a near-cosmopolitan parasitic
zoonosis that causes economic losses in many regions of
the world. This parasitic infection can be regarded as an
emerging or re-emerging disease causing considerable
losses in livestock production. CE is produced by the larval
cystic stage (hydatid) of the dog parasite Echinococcus
granulosus. After infective eggs are ingested, cysts develop
mainly in lungs and liver of humans and animals (sheep,
cattle, pigs, horses, etc). Infected people may require
surgery and/or Albendazole-based chemotherapy. In this
study, we evaluated the effects of Oxfendazole alone (an
antiparasitic drug used in animals), Oxfendazole plus
Praziquantel, and Albendazole plus Praziquantel against
hydatid cysts in sheep over 4 to 6 weeks of treatment. All
of the treatments in this study were efficacious in killing
the larval stages and, therefore, in minimizing the risk of a
dog acquiring new infections (taenias). These treatment
schemes can be added to control measures in animals and
eventually could be used for the treatment of human
infection. Further investigations on different schedules of
monotherapy or combined chemotherapy are needed, as
well as studies to evaluate the safety and efficacy of
Oxfendazole in humans.
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sheep of 90% (dead protoscoleces), and the 30% dead proto-
scoleces for the placebo group [24,25], the estimated sample size
was 10 for each study group. To compensate for some loss to
follow up, we enrolled between 25 to 32 sheep per group.
Necropsy procedures and cyst evaluation
Animals were slaughtered 4 to 8 weeks after their last treatment
in the official abattoir of the Tupac Amaru Cooperative. Sheep
were assigned correlative numbers in the slaughterhouse in order
to blind lung and liver cyst evaluations to all study personnel.
These codes were later matched with the originals (numbered ear
tag) for statistical analysis. Only one person (designated by the
principal investigator) was responsible for numbering the sheep
and later matching the codes.
All cysts from both livers and lungs were counted and registered on
individual sheets. Up to ten cysts per organ were measured (diameter)
andclassifiedaccordingtotheirmacroscopicappearanceandhydatid
fluid characteristics. For macroscopic evaluation, we used the des-
cription reported by Dueger and Gilman [24] of normal, calcified
and degenerated cysts. Normal cysts have a white inner layer filled
with clear liquid; presence of a calcareous deposit in the inner wall
denoted calcified cysts; and degenerated cysts had blackened walls
filled with turbid or purulent liquid and degraded membranes.
Fertility was assessed for the fluid of each evaluated hydatid cyst.
Hydatid fluid was placed in a 50 ml Falcon tube and gravity
sedimented for 30 minutes. Sediment of each cyst was observed
under a light microscope to look for PSCs. Cysts with PSCs were
defined as fertile, and cysts without PSCs were considered infertile
and not used for viability analysis. The cyst fertility percentage was
calculated for each group (fertile cysts/total cysts). Viability was
performed using a 0.1% aqueous eosin vital stain [28]. Dead,
nonviable PSCs stain red while those that are viable exclude the
dye and remain clear. The percentage of live PSCs divided by the
total PSCs (live PSC/total PSC) was used to calculate the percent
PSC viability for each cyst for both lung and liver.
Data analysis
All data analysis was performed according to a pre-established
analysis plan. We defined sheep infection status based on the
studies of Dueger and Gilman with some modifications [24].
When all the sheep’s fertile cysts had 0% PSC viability, they were
called ‘‘noninfective’’; sheep with all fertile cysts having 1% to
60% PSC viability were considered as ‘‘low-medium infective’’;
and sheep with all fertile cysts with more than 60% PSC viability
were called ‘‘highly infective’’. It has been previously shown that
without treatment the proportion of sheep with viable cysts is
generally higher than 60% [29–31], thus we used that cut-off to
create these categories of infective animals. For the purposes of this
study, the primary endpoint with respect to efficacy of any treated
group was the noninfective and/or low-medium infective sheep
rates as measured by the percentage of PSC viability.
Additionaly, the Kruskall-Wallis test was used to estimate the
difference in the number of cysts between treatment groups.
Analysis of Variance (ANOVA) was performed for cyst diameter
and Bonferroni multiple-comparison test was used to establish the
pair-group difference. The chi-square test was used to assess the
association of fertility and degenerated cysts (calcified and purulent
cysts included) with treatment groups. Logistic regression models
were used to estimate the odds of having degenerated or fertile
cysts; treatment and organ were the independent variables with
cluster in animal codes. For all the analyses, the significant
differences were set to less than 0.05. Percentages are presented
with their 95% confidence intervals.
Results
This study recruited a total of 118 Junin bred eight-tooth sheep
(28–48 month-old ewes) during the first week of June 2006. The
average mean weight was statistically similar among the groups at
the beginning of the study as determined by the Analysis of
Variance test. From the original 118 animals, only 92 were
examined in the slaughterhouse. Twenty-six sheep were lost or
had died due to non-treatment related causes such as other
infectious diseases and accidents. These 26 animals were equally
distributed among the groups as seen in Table 1. All animals were
similar in weight at the beginning of the study (Figure 1) and no
side effects were observed during the period of this trial. Animals
were followed-up 4 to 8 weeks after the last treatment.
After all the necropsies were performed the prevalence of CE
could be determined in the sheep. There were a total of 4 negative
sheep (no cysts either in lung or liver), yielding a CE prevalence of
95.7% (88/92). The percentage of dual infection (lung and liver)
was 84.8% (78/92). In the 88 positive sheep, there was a total of
1094 cysts (mean=12.4 cysts/animal), of which 592 (54.1%) were
pulmonary and 502 (45.9%) were hepatic, giving a lung-to-liver
ratio of 1.2:1. As seen in Table 2, there was no difference in the
number of cysts for either organ, lung or liver, between the
treatment and placebo groups. From those 1094 cysts in the whole
group, we only were able to evaluate 845 (441 pulmonary, and 404
hepatic cysts) due to logistic and lab facility constraints.
There was a statistically significant difference in the diameter for
both pulmonary and liver cysts as estimated by ANOVA (p,0.05).
The two drug-combination groups had significantly smaller pulmo-
nary cysts than placebo (means 18.9 mm for ABZ/PZQ, 17.9 mm
for OXF/PZQ vs 24.4 mm for placebo) (p,0.05) (Table 3). For liver
cysts, all of the treatment groups were similar to each other and all
had smaller hepatic cysts than the placebo group as demonstrated by
Bonferroni test (p,0.05). Hepatic cysts from OXF 60 mg, ABZ/
PZQ and OXF/PZQ were 11.1 mm, 7.7 mm and 13.6 mm smaller
than placebo group, respectively (Table 3).
Logistic regression analysis demonstrated that the odds of
having fertile cysts was similar between the treatment groups and
between the organs (lung and liver). Similarly, there was no
difference on the odds of having degenerated cysts between the
treatment groups and placebo. However, the odds of having
degenerated cysts was 70% higher in livers as compared to lungs
after controlling for treatment group (OR=1.7, 95% CI: 1.1–2.7,
p=0.02) (Table 4).
Table 1. Number of sheep at the pre- and post-treatment,
and number of lost and cystic echinococcosis-negative
animals in the trial.
Group
Pre-
treatment
a
Post-
treatment
b
Lost
(%)
c Negatives
PLACEBO 25 18 7 (28.0) 1
OXF 60 mg 31 25 6 (19.4) 0
ABZ30 mg+P Z Q 4 0 m g 3 02 82 ( 6 . 7 ) 0
OXF30 mg+P Z Q 4 0 m g 3 22 11 1 ( 3 4 . 4 ) 3
TOTAL 118 92 26 (22.0) 4
aPre-treatment: number of sheep that were treated at the beginning of this trial.
bPost-treatment: number of sheep that were evaluated and the end of this trial
at the slaughterhouse. Negative sheep are counted in this column.
cChi-square test showed no difference in the number of lost sheep between the
groups.
doi:10.1371/journal.pntd.0000616.t001
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viability than the placebo group for lung and liver cysts as shown in
Table 5 (p,0.05). Although treated groups had PSC viability
statistically similar each other for both lung and liver, the combination
of ABZ/PZQ exhibited the lowest PSCviability for lung cysts (12.7%),
while OXF/PZQ did for liver cysts (13.5%) (Table 5).
Taking only those sheep with fertile cysts, the proportion of
‘‘noninfective’’ sheep was 8.3%, 30%, 25% and 33.3% for placebo,
OXF60 mg, ABZ/PZQ and OXF/PZQ groups, respectively.
Additionally, the percentage of either ‘‘noninfective’’ or ‘‘low-
medium infective’’ sheep was only 50% for placebo, while these
rates were90%, 93.8%and 88.9%forOXF60 mg,ABZ/PZQand
Figure 1. Randomized clinical trial of infected sheep to evaluate Oxfendazole, praziquantel and albendazole against cystic
echinococcosis. The flowchart is presenting the phases of the clinical trial. The first part (starting on top) is showing the process and criteria of
sampling and assigning sheep to different treatment groups. The second part (in the middle) is presenting the group definitions, sample sizes and
follow up of the animals. The third part (on the bottom) is showing the last activities and number of animals per groups that were necropsied at the
end of the clinical trial.
doi:10.1371/journal.pntd.0000616.g001
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‘‘highly infective’’ sheep was near or less than 10% for treated
groups as compared to 50% for placebo one (Table 6). Also, the
combined-drug groups had a lower proportion of fertilecysts (ABZ/
PZQ–16/28, or 57.1%; OXF/PZQ–9/21, or 42.9%) than placebo
(12/18, or 66.7%) and OXF 60 mg (16/23, or 70%) though no
statistically difference was demonstrated.
Discussion
This study demonstrated that Oxfendazole at 60 mg/Kg, or the
combinations Oxfendazole/Praziquantel and Albendazole/Prazi-
quantel act against Cystic Echinoccosis in naturally-infected sheep.
All of the treatment schedules were able to reduce both hepatic
and pulmonary cyst size compared to placebo. Protoscolex
viability was lower statistically for all of the treatment schedules
than placebo animals for both lung and liver cysts. In the OXF
alone, ABZ/PZQ and OXF/PZQ groups, 90%, 93.8% and
88.9% of sheep, respectively, were either ‘‘noninfective’’ or ‘‘low-
medium infective’’ following treatment, compared to 50%
noninfective or low-medium infective animals in the placebo
group.
Oxfendazole was previously evaluated using different approach-
es and dosages in both sheep and goats. The longest trial used
OXF at 30 mg/Kg for eleven consecutive weeks [24] while the
other two used OXF at 30 mg/Kg twice a week for four weeks
[25,32]; all of them achieved high efficacy against CE (,90%). In
our trial, we increased the OXF dose (60 mg/Kg), and for the first
time evaluated the combination of OXF/PZQ. We obtained
similar results to those previous studies with efficacies of 90% and
88.9% for OXF 60 mg and OXF/PZQ, respectively.
Furthermore, we applied a more practical schedule using a less
intensive regimen (once weekly or biweekly), reducing not only the
treatment period but also minimizing the unnecessary animal
handling as compared to the three previous trials. Long treatment
periods in sheep are not only impractical but also costly in
developing countries where sheep are raised extensively in large
areas of land to minimize outlay and labor.
In terms of OXF phamacokynetics, this drug is stored in the
rumen of ruminants and it is detectable for up to seven days after
administration [22,33]. Therefore, we found no need to dose the
animals twice weekly as it has been done before [25]; instead we
dosed the animals once weekly and doubled the dose. Unfortu-
nately, there are no reports that describe the toxic level of OXF in
sheep, so we could not investigate higher doses of this drug.
In spite of variable ABZ effectiveness, the current chemotherapy
for human CE is 2–4 cycles of ABZ for 30 to 60 days with 15-days
breaks between cycles [5,14]. A review of ABZ uses found that the
Table 2. Total number of hydatid cysts and number of evaluated cysts for lung and liver by treatment group.
GROUP LUNG* LIVER* TOTAL
Total Evaluated Total Evaluated Total Evaluated
PLACEBO 112 87 107 87 219 174
OXF 60 mg 188 128 167 130 355 258
ABZ30 mg+PZQ40 mg 194 147 137 116 331 263
OXF30 mg+PZQ40 mg 98 79 91 71 189 150
TOTAL 502 441 502 404 1094 845
*Kruskall-Wallis test found no statistical difference in the total number of cysts between the groups for both lung or liver.
doi:10.1371/journal.pntd.0000616.t002
Table 3. Average diameter and standard deviation (SD) of
lung and liver cysts by treatment group.
GROUP LUNG LIVER
Mean 6 S.D n Mean 6 S.D n
PLACEBO
a 24.4617.6
c 87 27.8621.8
e 87
OXF 60 mg
b 20.3613.2
c 128 16.7612.0
f 130
ABZ30 mg+PZQ40 mg
b 18.9614.4
d 147 14.2611.5
f 116
OXF30 mg+PZQ40 mg
a 17.9614.5
d 79 20.1619.8
f 71
aMean diameter difference was not statistically significant between lung and
liver cysts evaluated by two-sample T-test for placebo and OXF/PZQ groups.
bLiver cysts were statistically smaller than lung cysts for OXF 60 mg and ABZ/
PZQ groups (p,0.05) as determined by two-sample t test.
cPlacebo group and OXF 60 mg had equal lung cyst diameters.
dABZ/PZQ and OXF/PZQ had statistically significant smaller lung cysts than the
placebo group (p,0.05), but they were similar in size to OXF 60 mg.
e,fAll treatment groups had statistically significant smaller liver cysts than the
placebo group (p,0.05), but there were no statistically significant differences
between treatment groups.
doi:10.1371/journal.pntd.0000616.t003
Table 4. Odds ratio of cyst fertility and cyst type (normal and
degenerated) according to treatment group and organ.
Dependent variable Group OR 95% CI p
Cyst fertility
a Placebo 1.0 - -
OXF 60 mg 0.5 0.2–1.5 0.25
ABZ/PZQ 0.6 0.2–1.6 0.32
OXF/PZQ 0.6 0.2–2.2 0.43
Lung 1.0 - -
Liver 0.8 0.6–1.1 0.23
Cyst type
b Placebo 1.0 - -
OXF 60 mg 1.7 0.6–4.5 0.28
ABZ/PZQ 2.0 0.8–5.4 0.16
OXF/PZQ 2.1 0.5–8.6 0.29
Lung 1.0 - -
Liver 1.7 1.1–2.7
c 0.02
aNo difference was found for treatment groups and organ for cyst fertility.
bNo difference was found for treatment groups for cyst type. Cyst type was
analyzed as normal and degenerated (calcified and purulent cysts).
cThe odds of having degenerated liver cysts was 70% higher than lung cysts
after controlling for treatment groups, statistically significant at p=0.02.
doi:10.1371/journal.pntd.0000616.t004
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between 22.4% to 50.0% remained unchanged [14]. A prospective
study carried out over 300 liver cysts, 42 abdominal cysts and 56
lung cysts found that 77.9% of the cysts, irrespective of their
localization, showed degenerative modifications after patients
received 10–12 mg/kg/day of ABZ without intervals for 3
months. Additionally, 30.9% recurred and 50% relapsed more
than once. Overall success was 49.3% while failure resulted in
31.5% of the patients [34].Although the cure rates of our study
were not the ultimate goal of treatment, they ranged between
25.0% to 33.3%, lower than those reported by Teggi et al [34]
with ABZ, but in a shorter regimen without any clinically
detectable side effect. Furthermore, OXF alone or the combina-
tions OXF/PZQ and ABZ/PZQ were able to significantly
decrease the cyst size as well as to reduce the number of viable
PSCs using a shorter regimen than the current use of ABZ.
However, this study’s conclusions are limited to ruminants for two
reasons. First, OXF is not licensed for human use and it must wait
until it is proven to be safety and efficacious in persons. Second,
OXF blood levels, phamacodynamic and phamacokinetics may be
different in monogastrics. It is, nevertheless, worthwhile to point
out the unknown potential of OXF or combinations in animal
intermediate hosts to spark the interest of other investigators.
Regarding drug combinations, the recommended dose of ABZ
for human CE is 10 mg/Kg to 15 mg/Kg while PZQ is
recommended at 25 mg/Kg to 40 mg/Kg [5]. However, a recent
review concluded that one of the major unanswered clinical
questions is whether the combination ABZ/PZQ is superior to
ABZ alone when both effectiveness and drug toxictiy are taken
into account [35]. In mice, PZQ and ABZ as combined therapy
against experimental hydatid disease was 100% effective as
chemoprophylactic treatment but no significant difference was
found to cure secondary experimental cystic echinococcosis [36].
In our study, the two combination therapies (ABZ/PZQ and
OXF/PZQ) were efficacious in curing or decreasing PSC viability
in already-infected sheep. However, we must point out that the
combination of OXF with PZQ might lack the necessary evidence
and the real mechanism against CE would require further
investigations. PZQ has the ability to increase the active
metabolite of ABZ (ABZ sulphoxide) up to 4.5-fold [5]; however,
no information is available about the effect of PZQ over OXF
metabolites. In spite of the high doses used in this trial, no side
effects were observed in any of the animals suggesting that all of
the therapeutic schemes were safe at least for sheep.
Our trial demonstrated that both pulmonary and hepatic cysts
from treated groups were reduced in size as compared to those
from the placebo. Although that difference might not be clinically
relevant (approximately 10 mm in diameter for hepatic cysts), cyst
reduction is one of the indicators of successful treatment as
evidenced in chemotherapy studies in humans. For instance, a
study evaluating the timing and degenerative changes in the cysts
after patients received benzimidazole treatment demonstrated that
abdominal cysts (,5 cm diameter) became smaller after 3.3–9.3
months [37]. We furthermore showed that the decreased cyst
diameter can be observed in a relatively short period of time (4–8
weeks). Although our treatment options are not yet applicable to
humans, future clinical trials in humans or animals might take our
results as a reference.
Another interesting application of chemotherapy may be as part
of a control program. For instance, PZQ treatment of dogs will
stop new infections in sheep but will not affect the reservoir of cysts
present in already-infected sheep [38]. On the other hand, sheep
cystic echinococcosis can be prevented by using a highly effective
vaccine [39], but to date it has not been used in any national
control program due to both cost and logistics. Furthermore,
infection acquired before sheep vaccination can still be transmitted
to dogs, and it can take up to 15 years before all cyst reservoirs
(infected sheep) disappear from a specific herd [38]. Therefore,
protoscolicidal drugs, such as OXF or the combinations of ABZ/
PZQ and OXF/PZQ, might be additional strategies to for control
programs. Efficacious, inexpensive, and practical and expeditious
treatments may reduce the number of viable PSCs. These
‘‘noninfective’’ offal from infected sheep will be less likely to yield
new taenias, decreasing the number of dogs infected and/or the
number of worms found in susceptible dogs.
Although we did not find any significant difference in the
number of cyst between the groups, it is very likely that the
number and size of the cysts may have been different between
groups from the beginning of the experiment. Both characteristics -
number and size - are time-dependent, thus sheep aged 2 years
would have had fewer and smaller cysts than sheep aged 4 years or
older, even if randomization was appropriately applied in field. We
were not be able to differentiate the exact age in these group of
sheep since we used tooth eruption as a surrogate of the age. All
selected animals had eight-tooth already erupted, meaning they
Table 5. Grouped-average PSC viability by organ and
treatment group.
Group % of PSC viability by organ
Lung Liver
PLACEBO 58.4
a 45.9
c
OXF 60 mg 23.8
b 15.1
d
ABZ30 mg+PZQ40 mg 12.7
b 18.8
d
OXF30 mg+PZQ40 mg 15.6
b 13.5
d
a,bPlacebo group for lung cysts was statistically larger than any of the treatment
groups (p,0.05), but all treated groups were similar to each other.
c,dPlacebo group for liver cysts was statistically different from each of the three
treatment groups (p,0.05), but the treated groups were similar to each
other.
doi:10.1371/journal.pntd.0000616.t005
Table 6. The effect of Oxfendazole, ABZ plus PZQ and OXF
plus PZQ on sheep cystic echinococcosis as measured by PSC
viability.
Group (n)
Nu of sheep
with fertile
cysts
Non-
infective
b
Low-
medium
infective
c
Highly
infective
d
PLACEBO (18) 12 1 (8.3%) 5 (41.7%) 6 (50.0%)
OXF 60 mg (25) 20 6 (30.0%) 12 (60.0%) 2 (10.0%)
ABZ30 mg+PZQ40 mg (23) 16 4 (25.0%) 11 (68.8%) 1 (6.3%)
OXF30 mg+P Z Q 4 0m g( 2 8 ) 9 3( 3 3 . 3 % ) 5( 5 5 . 6 % ) 1( 1 1 . 1 % )
aNo difference was found in the number of sheep between the groups and the
final condition (noninfective, low-medium infective, highly infective) by using
the chi-square test.
b,cNo difference was demonstrated between any of the treated groups and the
placebo group by means of two-sample test of proportion. However, when
adding noninfective and low-medium infective sheep, each of the treatment
groups was significantly higher than placebo group (p,0.05).
dOXF 60 mg and ABZ/PZQ had statistically significant lower proportions of
highly infective sheep than did the placebo group (p,0.05) by two-sample
test of proportion. OXF/PZQ group was close to the borderline as compared to
placebo (p=0.06).
doi:10.1371/journal.pntd.0000616.t006
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results, probably by overestimating the drugs’ efficacies. As shown
by Torgerson et al in a mathematical simulation [40], there is high
probability of a substantial difference in worm burdens if allocations
are undertaken randomly at the beginning of any clinical trial. It
was demonstrated that even with identical initial experimental
infections with Haemonchus contortus in sheep, fewer worms
established in one of the groups (Moxidectin) as compared to the
other groups (Ivermectin, Mebendazole, and control) before the
onset of treatment. Thus, the apparent parasitic reduction in our
trial could be overestimated since some sheep may have had fewer
cysts initially; hence drug efficacy may also be overestimmated. It is
already known that the distribution of macroparasites over their
host population is highly aggregated in naturally infected animals
[41]. We would, therefore, suggest that more exact age determi-
nation be used and that sheep should be assigned to groups on the
basis of age-matching in future animal clinical trials.
One of the limitations of our study is the short time between
final treatment dose and animal sacrifice. A trial evaluating PZQ
and ABZ in sheep waited up to 7 months before slaughtering the
animals to allow any residual live parasites to recover [42]. Since
we evaluated the animals only 4 to 8 weeks after treatment, we do
not know whether the effect of the drugs might have been
prolonged or whether surviving parasites (viable PSCs) would re-
activate cysts in the future. Additionally, the absence of living
PSCs in a cyst does not mean the cyst is dead or inactive, merely
that the germinal layer is not producing PSCs at the time. For a
cyst to be non-viable, one would need to show that the totality of
the cyst is incapable of re-establishing the infection for a period of
time, or to demonstrate histologically the complete destruction and
degeneration of the germinal layer. Unfortunately, this study was
not able to produce that information and thus we refer to ‘‘PSC
viability’’ instead of ‘‘cyst viability’’ to evaluate the efficacy of the
drugs. Another limitation of our study is the lack of information of
pharmacokinetic, pharmacodynamic, and toxicity data of OXF
when combined with other antiparasitic drugs in other animal
species. Thus we might not have sufficient background to select the
appropriate dose of OXF when combining with PZQ.
In summary, this trial demonstrates that Oxfendazole at
60 mg/kg and the combined therapies of Oxfendazole +
Praziquantel (30 mg/Kg + 40 mg/Kg) and Albendazole +
Praziquantel (30 mg/Kg + 40 mg/Kg) are successful agents that
can be added to current control measures to interrupt the
transmission of Echinococcus granulosus. It also demonstrates the
potential of these antiparasitic drugs to be used in the treatment of
Cystic Echinococcosis in a relatively short period of time, reducing
the cost of the therapy. Further investigations of varying doses of
monotherapy and combined chemotherapy are needed, as well as
evaluation of the efficacy and safety of OXF in humans.
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